Endonovo Therapeutics, Inc. (ENDV) Financial Statements (2024 and earlier)

Company Profile

Business Address 6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 32,60210,9429823,139 59,982
Cash and cash equivalents 32,60210,9429823,139 59,982
Receivables  3,120 944945945
Other undisclosed current assets40,23181,11015,724 5,0003,500
Total current assets:72,83395,17215,82224,0835,94564,427
Noncurrent Assets
Intangible assets, net (including goodwill)941,9881,103,7161,265,4441,427,1721,588,9001,750,628
Intangible assets, net (excluding goodwill)941,9881,103,7161,265,4441,427,1721,588,9001,750,628
Total noncurrent assets:941,9881,103,7161,265,4441,427,1721,588,9001,750,628
TOTAL ASSETS:1,014,8211,198,8881,281,2661,451,2551,594,8451,815,055
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:  879,2054,426,8457,425,5656,851,6246,223,876
Interest and dividends payable3,279,9063,032,7962,759,929
Accounts payable   884,195865,753786,032704,018
Accrued liabilities   3,542,6503,279,9063,032,7962,759,929
Other undisclosed accounts payable and accrued liabilities  879,205    
Debt   7,041,1457,123,4337,237,2047,169,953
Deferred compensation liability  4,553,6234,442,6064,355,9234,210,2614,042,411
Derivative instruments and hedges, liabilities5,902,8299,322,39317,359,0645,235,6945,289,2614,972,655
Due to related parties112,100116,600119,600123,100
Other undisclosed current liabilities17,233,92710,732,750 (3,279,906)(3,032,796)(2,759,929)
Total current liabilities:23,136,75625,487,97133,381,76020,977,30920,675,15419,772,066
Noncurrent Liabilities
Liabilities, other than long-term debt79,82579,82579,82579,82579,82579,825
Other liabilities   79,825   
Business combination, contingent consideration, liability79,82579,825 79,82579,82579,825
Total noncurrent liabilities:79,82579,82579,82579,82579,82579,825
Total liabilities:23,216,58125,567,79633,461,58521,057,13420,754,97919,851,891
Equity
Equity, attributable to parent, including:(22,201,760)(24,368,908)(32,180,319)(19,605,879)(19,160,134)(18,036,836)
Common stock27,88027,02821,32215,92215,0428,132
Common stock, share subscribed but unissued, subscriptions receivable      (1,570)
Additional paid in capital43,636,32343,533,68742,919,08642,365,85942,209,12440,813,201
Accumulated deficit(65,864,419)(67,928,079)(75,119,183)(61,986,116)(61,382,756)(58,856,625)
Stockholders' equity note, subscriptions receivable(1,570)(1,570)    
Other undisclosed equity, attributable to parent2626(1,544)(1,544)(1,544)26
Total equity:(22,201,760)(24,368,908)(32,180,319)(19,605,879)(19,160,134)(18,036,836)
TOTAL LIABILITIES AND EQUITY:1,014,8211,198,8881,281,2661,451,2551,594,8451,815,055

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues45,20087,540121,46310,9606502,282
Cost of revenue (3,996)(4,866)(4,027)(383)(714)
Gross profit:45,20083,544116,5976,9332671,568
Operating expenses(1,176,509)(612,834)(599,648)(503,711)(1,799,016)(487,330)
Operating loss:(1,131,309)(529,290)(483,051)(496,778)(1,798,749)(485,762)
Nonoperating income (expense)3,194,9697,759,792(12,449,084)(106,582)(727,382)(1,927,447)
Other nonoperating expense(15,328)(9,190)(16,389)(30,879)(178,000) 
Interest and debt expense 103,60252,460 319,081104,760(60,947)
Income (loss) from continuing operations before equity method investments, income taxes:2,167,2627,282,962(12,932,135)(284,279)(2,421,371)(2,474,156)
Other undisclosed income (loss) from continuing operations before income taxes (103,602)(52,460) (319,081)(104,760)60,947
Income (loss) from continuing operations:2,063,6607,230,502(12,932,135)(603,360)(2,526,131)(2,413,209)
Loss before gain (loss) on sale of properties:(603,360)(2,526,131)(2,413,209)
Net income (loss) available to common stockholders, basic:2,063,6607,230,502(12,932,135)(603,360)(2,526,131)(2,413,209)
Dilutive securities, effect on basic earnings per share(3,106,695)(7,727,261)    
Net loss available to common stockholders, diluted:(1,043,035)(496,759)(12,932,135)(603,360)(2,526,131)(2,413,209)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):2,063,6607,230,502(12,932,135)(603,360)(2,526,131)(2,413,209)
Comprehensive income (loss), net of tax, attributable to parent:2,063,6607,230,502(12,932,135)(603,360)(2,526,131)(2,413,209)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: